ISOSORBIDE MONONITRATE tablet, extended release

Страна: Соединенные Штаты

Язык: английский

Источник: NLM (National Library of Medicine)

Купи это сейчас

Активный ингредиент:

ISOSORBIDE MONONITRATE (UNII: LX1OH63030) (ISOSORBIDE MONONITRATE - UNII:LX1OH63030)

Доступна с:

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

ИНН (Международная Имя):

ISOSORBIDE MONONITRATE

состав:

ISOSORBIDE MONONITRATE 60 mg

Администрация маршрут:

ORAL

Тип рецепта:

PRESCRIPTION DRUG

Терапевтические показания :

Isosorbide Mononitrate Extended-Release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Isosorbide Mononitrate Extended-Release Tablets are contraindicated in patients who have shown hypersensitivity or idiosyncratic reactions to other nitrates or nitrites.

Обзор продуктов:

Isosorbide Mononitrate Extended-Release Tablets, USP 30 mg are White, biconvex oval shaped tablets, scored and embossed "30" on one side. Bottles of 30 NDC 23155-519-03 Bottles of 100 NDC 23155-519-01 Bottles of 500 NDC 23155-519-05 Isosorbide Mononitrate Extended-Release Tablets, USP 60 mg are Light yellow, biconvex oval shaped tablets, scored on both sides and embossed ‘DX 31’ on one side. Bottles of 90 NDC 23155-178-09 Bottles of 100 NDC 23155-178-01 Bottles of 500 NDC 23155-178-05 Isosorbide Mononitrate Extended-Release Tablets, UPS 120 mg are white, biconvex, oval-shaped tablets, embossed with '120' on one side. Bottles of 100 NDC 23155-628-01 Store at 20° to 25°C (68° to 77°F) (see USP Controlled Room Temperature). Protect from excessive moisture. Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816, 1.866.901.DRUG (3784) Manufactured by: Dexcel Ltd. 1 Dexcel St. Or-Akiva, 3060000, Israel. Revised: 10/2021

Статус Авторизация:

Abbreviated New Drug Application

Характеристики продукта

                                ISOSORBIDE MONONITRATE- ISOSORBIDE MONONITRATE TABLET, EXTENDED
RELEASE
HERITAGE PHARMACEUTICALS INC. D/B/A AVET PHARMACEUTICALS INC.
----------
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS, USP
RX ONLY
DESCRIPTION
Isosorbide mononitrate (ISMN), an organic nitrate and the major
biologically active
metabolite of isosorbide dinitrate (ISDN), is a vasodilator with
effects on both arteries
and veins.
Each tablet, for oral administration, contains either 30 mg, 60 mg or
120 mg of
isosorbide mononitrate in an extended-release formulation. In
addition, ISMN 30 mg
tablets, USP contains the following inactive ingredients: colloidal
silicon dioxide,
compressible sugar, hydroxypropyl methylcellulose, lactose
monohydrate, magnesium
stearate. ISMN 60 mg tablets, USP contains the following inactive
ingredients: colloidal
silicon dioxide, compressible sugar, hydroxypropyl methylcellulose,
lactose
monohydrate, magnesium stearate, yellow iron oxide. ISMN 120 mg
tablets, USP
contains the following inactive ingredients: colloidal silicon
dioxide, hydroxypropyl
cellulose, hypromellose, lactose monohydrate, magnesium stearate and
talc.
The molecular formula of ISMN is C H NO and the molecular weight is
191.14. The
chemical name for ISMN is: 1,4:3,6-dianhydro-,D-glucitol 5-nitrate;
the compound has
the following structural formula:
ISMN is a white, crystalline, odorless compound which is stable in air
and in solution, has
a melting point of about 90°C, and an optical rotation of +144° (2%
in water, 20°C).
Isosorbide mononitrate is freely soluble in water, ethanol, methanol,
chloroform, ethyl
6
9
6
acetate, and dichloromethane. Isosorbide Mononitrate Extended-Release
120mg Tablets,
USP meets USP Dissolution Test 7.
FDA approved dissolution acceptance criteria for Isosorbide
Mononitrate Extended-
Release 30mg and 60mg Tablets, USP differ from that of the USP.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
The Isosorbide Mononitrate Extended-Release Tablet, USP is an oral
extended-release
formulation of ISMN, the major active metabolite
                                
                                Прочитать полный документ
                                
                            

Поиск оповещений, связанных с этим продуктом